Brokerages Set KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) PT at $29.40

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) has earned a consensus rating of “Moderate Buy” from the eight ratings firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and seven have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $29.40.

A number of research firms have weighed in on KALV. HC Wainwright raised their price objective on shares of KalVista Pharmaceuticals from $27.00 to $37.00 and gave the stock a “buy” rating in a report on Friday, January 9th. Wall Street Zen upgraded shares of KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, December 6th. Needham & Company LLC increased their target price on shares of KalVista Pharmaceuticals from $28.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, January 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Thursday, January 22nd. Finally, TD Cowen restated a “buy” rating on shares of KalVista Pharmaceuticals in a research report on Wednesday, December 3rd.

Insider Buying and Selling

In other news, insider Nicole Sweeny sold 3,975 shares of the business’s stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $15.57, for a total value of $61,890.75. Following the transaction, the insider owned 47,003 shares of the company’s stock, valued at approximately $731,836.71. The trade was a 7.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Benjamin L. Palleiko sold 10,034 shares of the company’s stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $15.57, for a total value of $156,229.38. Following the sale, the chief executive officer owned 442,883 shares of the company’s stock, valued at $6,895,688.31. This trade represents a 2.22% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 33,378 shares of company stock valued at $522,290. Company insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On KalVista Pharmaceuticals

A number of large investors have recently bought and sold shares of KALV. BNP Paribas Financial Markets lifted its stake in shares of KalVista Pharmaceuticals by 47.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock worth $46,000 after acquiring an additional 1,292 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of KalVista Pharmaceuticals during the third quarter worth about $55,000. Wolverine Asset Management LLC purchased a new position in KalVista Pharmaceuticals during the third quarter worth about $57,000. Truvestments Capital LLC raised its holdings in KalVista Pharmaceuticals by 253.8% during the fourth quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company’s stock worth $76,000 after purchasing an additional 3,360 shares in the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new stake in KalVista Pharmaceuticals in the third quarter valued at about $63,000.

KalVista Pharmaceuticals Stock Down 1.1%

Shares of NASDAQ KALV opened at $18.24 on Friday. The business has a 50-day moving average of $15.70 and a two-hundred day moving average of $14.22. The company has a market capitalization of $922.03 million, a price-to-earnings ratio of -4.62 and a beta of -0.35. KalVista Pharmaceuticals has a 1 year low of $9.23 and a 1 year high of $19.00. The company has a debt-to-equity ratio of 8.18, a current ratio of 7.22 and a quick ratio of 7.21.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.